BioStock: Elicera Therapeutics takes immuno-oncology to the next level
Immuno-oncology is a vast and promising field within cancer therapeutics. Over the last decade, the progress made in the field has given new hope to cancer patients all over the world. However, there is still a significant push towards even better treatments, and the Swedish biotech Elicera Therapeutics is part of this using advanced immuno-oncology technology to develop novel drug solutions.
Read the full interview with Elicera's CEO Jamal El-Mosleh at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se